ArticlePharmacy (Basel, Switzerland)2025

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients.

Tamather Almandeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.